Antitumor T cells are subject to multiple mechanisms of negative regulation [1] [2] [3] . Recent findings that innate lymphoid cells (ILCs) regulate adaptive T cell responses [4] [5] [6] led us to examine the regulatory potential of ILCs in the context of cancer. We identified a unique ILC population that inhibits tumor-infiltrating lymphocytes (TILs) from high-grade serous tumors, defined their suppressive capacity in vitro, and performed a comprehensive analysis of their phenotype. Notably, the presence of this CD56 + CD3 − population in TIL cultures was associated with reduced T cell numbers, and further functional studies demonstrated that this population suppressed TIL expansion and altered TIL cytokine production. Transcriptome analysis and phenotypic characterization determined that regulatory CD56 + CD3 − cells exhibit low cytotoxic activity, produce IL-22, and have an expression profile that overlaps with those of natural killer (NK) cells and other ILCs. NKp46 was highly expressed by these cells, and addition of anti-NKp46 antibodies to TIL cultures abrogated the ability of these regulatory ILCs to suppress T cell expansion. Notably, the presence of these regulatory ILCs in TIL cultures corresponded with a striking reduction in the time to disease recurrence. These studies demonstrate that a previously uncharacterized ILC population regulates the activity and expansion of tumor-associated T cells.
ILCs have been classified into three groups with diverse phenotypes and functions 7 . Group 1 includes both cytotoxic NK cells and ILC1s, which also produce interferon (IFN)-γ but are not cytotoxic. Group 2 (ILC2) cells produce IL-4, IL-5, IL-9, and IL-13, and group 3 (ILC3) cells produce IL-22 alone or in combination with IL-17A. These definitions have been complicated by recent studies demonstrating that ILC3 cells can acquire an ILC1-like phenotype (ex-ILC3), that ILC1s exhibit cytotoxicity under certain conditions, and that markers previously used to differentiate ILC populations are often specific to particular immune contexts or tissues 8 . Therefore, the properties that differentiate ILC populations are still poorly understood, particularly in humans.
A dynamic relationship of NK cells and other ILCs with T cells has been described 4, 5 . Importantly, in addition to promoting T cell responses, NK cells can inhibit T cell-mediated immune responses in a variety of contexts, including autoimmunity [9] [10] [11] [12] , transplantation 13, 14 , and viral infection [15] [16] [17] [18] [19] [20] [21] . The significance of NK cell-mediated regulation of T cells has recently been highlighted by mouse studies demonstrating that in vivo depletion of NK cells can improve antiviral T cell responses and result in the clearance of lymphocytic choriomeningitis virus (LCMV) clone 13, which normally establishes a chronic infection 19, 20 . In humans, NK cells from patients with chronic hepatitis B virus (HBV) infection can kill HBV-specific CD8 + T cells in a TRAIL-receptor-dependent manner 22 , and type I interferon treatment of hepatitis C virus (HCV)-infected patients can lead to activation of NK cells and reduced production of IFN-γ by CD4 + T cells 23 . Other reports link activated ILCs with a reduced susceptibility to graft-versus-host disease 24 , and ILC3s were shown to limit CD4 + T cell responses to intestinal, commensal bacteria 25 , thus supporting a role for non-NK cell ILCs in regulating adaptive responses.
While evaluating the potential of TIL-based adoptive T cell therapy to treat ovarian cancer, we observed a correlation between the presence of CD56 + CD3 − cells and poor TIL expansion. TIL cultures from primary high-grade serous cancer (HGSC) were grown using established protocols 26 , and the expansion rates and phenotype of the cells present within TIL cultures were assessed (Fig. 1a-e and Supplementary Fig. 1) . A considerable proportion of HGSC TIL cultures grew slowly or failed to expand (Fig. 1a) and would therefore not meet criteria for use in adoptive cell therapy. TIL cultures that grew slowly generally corresponded to cultures with a high proportion of CD56 + CD3 − cells (Fig. 1b,c) , whereas no association with growth rate was observed for CD14 + or CD19 + populations in TIL cultures (Fig. 1d) . Further analysis demonstrated that a high proportion of A distinct innate lymphoid cell population regulates tumor-associated T cells CD56 + CD3 − cells was associated with a reduction in the proportion of CD4 + TILs and, to a greater degree, the proportion of CD8 + TILs (Fig. 1e) . Both rapidly growing TIL cultures and those that grew slowly or showed no expansion (slow/no expansion) exhibited a range in the proportion of CD56 + CD3 − cells and the proportion of CD56 + CD3 − cells did not have a linear correlation with expansion rate, suggesting that CD56 + CD3 − cells in TIL cultures with slow/no expansion differ from CD56 + CD3 − cells in rapidly expanding cultures in their function.
To address the possibility that some patients had suppressive CD56 + CD3 − cells, TIL cultures with slow/no expansion were cultured with and without depletion of CD56 + CD3 − cells and with irradiated feeder cells, anti-CD3 monoclonal antibody (mAb), and IL-2. This protocol is similar to ones used to rapidly expand TIL cultures immediately before cell infusion in clinical trials. TIL expansion increased in the absence of CD56 + CD3 − cells (Fig. 1f) . In the majority of patients, an increase in CD4 + and CD8 + TIL expansion was observed in the absence of CD56 + CD3 − cells, but a statistically significant increase in the expansion was noted only for CD8 + TILs (Fig. 1g) .
To examine whether these CD56 + CD3 − cells could suppress T cells that received a 'strong' proliferative signal and evaluate whether suppression was linked to the presence of antigen-presenting cells (APCs) or IL-2, we performed assays similar to in vitro regulatory T cell (T reg ) suppression assays. TIL cultures that did not expand well were depleted of CD56 + CD3 − cells and then activated with anti-CD3-and anti-CD28-coated beads. CD56 + CD3 − cells were then added back at a ratio of one CD56 + CD3 − cell to four T cells. The addition of CD56 + CD3 − cells suppressed CD4 + and CD8 + TIL expansion in the absence of APCs or exogenous IL-2 ( Fig. 1h and Supplementary Fig. 2 ), indicating that CD56 + CD3 − cells from cultures with limited TIL expansion were capable of directly suppressing T cell proliferation. This capacity to inhibit T cell expansion was not shared by CD56 + CD3 − cells from rapidly expanding TIL cultures or when peripheral blood (PB) NK cells were co-cultured with autologous PB T cells (Supplementary Fig. 3a,b) , supporting the interpretation that CD56 + CD3 − cells from slowly expanding TIL cultures represent a distinct regulatory population.
NK cells and other ILCs can contribute to the initiation and polarization of the adaptive immune response 4, 5 ; therefore, experiments were done to evaluate cytokine production in TIL cultures with slow/no expansion versus those that expanded well. TIL cultures that exhibited slow/no expansion and also contained a high proportion of CD56 + CD3 − cells had lower amounts of IFN-γ, tumor necrosis factor (TNF)-α, IL-4, IL-5, IL-10, and IL-13 but higher amounts of IL-6 (Fig. 2a) . To determine whether CD56 + CD3 − cells from TIL cultures with slow/no expansion directly regulated TIL cytokine production, sorted CD56 + CD3 − cells were co-cultured with autologous CD3 + CD56 − TILs and activated with anti-CD3-and anti-CD28-coated beads. The percentages of CD4 + and CD8 + TILs that were TNF-α + IFN-γ + were lower in the presence of CD56 + CD3 − cells (Fig. 2b-d) . Therefore, CD56 + CD3 − cells from cultures with slow/no expansion can directly alter cytokine production by CD4 + and CD8 + TILs.
To interrogate unique and overlapping properties for suppressive CD56 + CD3 − cells from TIL cultures undergoing slow/no expansion (regulatory CD56 + CD3 − cells) and non-suppressive CD56 + CD3 − cells from rapidly expanding TIL cultures (CD56 + CD3 − cells), we performed transcriptome profiling of these populations from six independent donors using RNA-seq (Fig. 3a-d and Supplementary Fig. 4) .
Comparison of the fold change in gene-level expression for the two CD56 + CD3 − cell populations revealed a set of significantly differentially expressed genes that distinguished regulatory CD56 + CD3 − cells from nonregulatory CD56 + CD3 − cells, confirming the idea that these two populations are distinct from one another (Fig. 3a) . The transcriptome profiles of regulatory CD56 + CD3 − cells from three independent donors were remarkably similar, supporting a unique but shared pattern of gene expression among different individuals. When expression of NK cell-and ILC-associated molecules was examined, both populations of CD56 + CD3 − cells had high transcript-level expression of NK cell-associated genes, including natural cytotoxicity receptors (NCRs), members of the NKG2-CD94 family, and killer cell Ig-like receptors (KIRs) (Fig. 3b,c) . High expression of NCR1 (NKp46), NCR3 (NKp30), KLRK1 (NKG2D), KLRC1 (NKG2A), KLRD1 (CD94), KIR genes, and CD7 and low FCGR3A (CD16) expression were confirmed by flow cytometry (Supplementary Figs. 5 and 6 (Fig. 3d) . While the regulatory CD56 + CD3 − population was able to suppress antitumor T cells, FOXP3 could not be detected at either the transcript or protein level ( Fig. 3d and Supplementary Fig. 7 ), indicating that this T reg -lineage-defining transcription factor [28] [29] [30] is not required for ILC-mediated suppression.
To examine cytokine production by the regulatory CD56 + CD3 − population, CD56 + CD3 − cells were sorted from TIL cultures that did not expand well and cultured overnight in medium containing IL-2. Regulatory CD56 + CD3 − cells produced minimal IFN-γ, but they secreted high amounts of IL-9 and IL-22 and low amounts of IL-5, IL-13, and IL-17A (Fig. 3e) . Despite producing cytokines characteristic of ILC2 and ILC3 cells, regulatory CD56 + CD3 − cells produced very high levels of CCL3 (Supplementary Fig. 8 ), which is reportedly expressed by ILC1s but not by ILC3s 31 .
Cytokine expression was further assessed by intracellular cytokine staining. Sorted CD56 + CD3 − cells were restimulated with phorbol myristate acetate (PMA) and ionomycin for 5-6 h. TNF-α and IFN-γ expression could be induced in the ILC populations; however, the two ILC populations differed in the proportions of cells that expressed TNF-α alone, IFN-γ alone, or both TNF-α and IFN-γ (Fig. 3f,g ). Stimulated regulatory CD56 + CD3 − cells produced IL-22, whereas nonregulatory CD56 + CD3 − cells did not, supporting the notion that expression of this cytokine may be a characteristic of regulatory CD56 + CD3 − cells (Fig. 3h,i ). Yet, when analyzed ex vivo, regulatory CD56 + CD3 − cells were NKp44 − (Supplementary Fig. 6c ), distinguishing them from ILC3s 7 . Low IL-9 expression was detected by regulatory CD56 + CD3 − cells in three of five donors, but neither regulatory CD56 + CD3 − nor nonregulatory CD56 + CD3 − cells produced detectable IL-17A under these conditions (Fig. 3h) . Therefore, this regulatory CD56 + CD3 − population expresses many NK cell-associated receptors but clearly has unique features, including a gene expression signature that distinguishes these cells from nonsuppressive CD56 + CD3 − cells and a unique cytokine and chemokine profile in relation to that of other described ILCs.
A variety of mechanisms have been reported that govern NK cell-mediated T cell regulation. An IL-2-and contact-dependent mechanism was reported in NK cell regulation of T cell responses to human parainfluenza virus type 3 infection 31 . Other studies have observed IL-10-mediated suppression, indirect suppression mediated by dendritic cells (DCs), and suppression via receptors including 2B4, NKG2D, and NKp46 (refs. 17,19-21) . RNA-seq analysis showed that there were high levels of transcripts associated with cytotoxicity, including for granzyme A, granzyme B, and perforin, in the regulatory CD56 + CD3 − population (Fig. 4a) . Therefore, we assessed the cytotoxic potential of these cells. "Fast" expansion rates refers to TIL cultures that yielded >30 × 10 6 cells on or before 4 weeks in culture, "slow" refers to TIL cultures that yielded 2-29 × 10 6 cells by 4 weeks, and "no" refers to cultures that had cell yields <2 × 10 6 cells at 4 weeks. For cultures that were harvested before or after 4 weeks, the cell counts at the time of harvest were used to estimate whether the culture would have been categorized as "fast", "slow", or "no" at the 4-week mark. were sorted from TIL cultures that expanded slowly and were cocultured with target K562 cells in the presence of IL-2. Regulatory CD56 + CD3 − cells had low CD107a expression after co-culture and induced minimal K562 cell death ( Fig. 4b-d) . In comparison, PB NK cells expressed high levels of CD107a and demonstrated strong cytotoxicity against K562 cells. IL-10 expression by regulatory CD56 + CD3 − cells was not observed at either the transcript or protein level ( Fig. 3e and Supplementary  Fig. 9a) , and there was no increase in TGFB1 transcript levels when compared to nonregulatory CD56 + CD3 − cells (Supplementary Fig. 9b ).
The unique cytokine expression profile of regulatory CD56 + CD3 − cells, however, suggested that regulatory CD56 + CD3 − cells might suppress T cells via a secreted factor. To address this possibility, CD56 + CD3 − cells from TIL cultures with slow/no expansion were sorted by flow cytometry and plated; then, supernatants were collected at 16 h. The expansion and cytokine production of autologous flow cytometry-sorted CD56 − CD3 + TILs was then assessed after incubation with and without the supernatants from regulatory CD56 + CD3 − cells. No difference in either proliferation or cytokine production was observed (Fig. 4e,f) . NCR1  NCR2  NCR3  KLRK1  KLRC1  KLRC2  KLRD1  NCAM1  KLRG1  ITGA2  B3GAT1  SELL  CCR7  KIT  CXCR3  NFIL3  CCR6  KLRB1  CD226  GFI1  ZBTB16  ID2  BCL11B  RUNX3  TOX   SIGLEC17P  HIST2H2BD  RP11-95M15.2  DNAH2  COL18A1  HSPA2  COL11A2  RAB26  FAM43A  IER5L  CTSL  C16orf93  TTN  JUNB  JUN  COL9A2  KIAA1683  MST1  RHOB  XKR6  KANK3  FOSB  ADAMTS17  MAFB  SNAI1  DUSP1  MYO15B  USP35  FOS  PLEC  RTN4RL1  JUND  TPM2  UBASH3A  TMEM206  PLA2G4B  JAKMIP2  IER2  ABCA2  TBKBP1  HEXIM1  CCDC130  ABCA7  CAPN12  PLCH2  NPIPB3  REXO2  CLIP2  JAG2  GADD45B  TNFRSF18  ZFYVE27  SYTL1  HSPA1A  DEDD2 For box-and-whisker plots in g and i, the middle line indicates median, the box extends from the 25th to 75th percentile, and whiskers indicate minimum to maximum values. Statistical significance in g and i was determined by Mann-Whitney test.
Regulatory CD56 + CD3 − cells had high expression at the transcript and protein levels of NKG2D (KLRK1), as well as NKp30 (NCR3) and NKp46 (NCR1) (Fig. 4g,h) , two NCRs implicated in the interaction between NK cells and other immune cells 21, 32, 33 . Therefore, we examined whether these receptors were involved in TIL suppression. TIL cultures with high proportions of CD56 + CD3 − cells and slow/no expansion were activated with irradiated feeder cells, anti-CD3 mAb, and IL-2 in the presence or absence of anti-NKG2D, anti-NKp30, and antiNKp46 antibodies (Fig. 4i) . Addition of anti-NKG2D antibody to the cultures increased T cell expansion in six of seven patients. As T cells also express NKG2D and anti-NKG2D antibody can be an agonist for T cells, the effects of anti-NKG2D antibody on T cells versus regulatory CD56 + CD3 − cells could not be distinguished. However, T cells express neither NKp30 nor NKp46. Addition of anti-NKp30 antibody . (j) RFS was analyzed in patients with HGSC whose TIL cultures contained (n = 6) or did not contain (n = 10) regulatory CD56 + CD3 − cells. Patients were chemotherapy naive at the time of TIL isolation, and surgery achieved optimal debulking. For box-and-whisker plots in c, d, and h, the middle line indicates the median, the box extends from 25th to 75th percentile, and the whiskers indicated minimum to maximum values. Statistical significance was determined by Mann-Whitney test for c, d, g and h, Wilcoxon matched-pairs signed-rank test for e and i, and log-rank (Mantel-Cox) test in j. n.s., not significant.
increased the expansion yields of T cells in four of seven patients but reduced the yields in two patients. Notably, anti-NKp46 treatment resulted in T cell expansion yields comparable to those achieved by depletion of CD56 + CD3 − cells in all seven patients (Fig. 1f) , demonstrating that anti-NKp46 treatment interferes with the activity of regulatory CD56 + CD3 − cells. Therefore, the interactions of NKG2D, NKp30, and particularly NKp46 may promote the suppression of TIL expansion that is mediated by regulatory CD56 + CD3 − cells.
The ability of regulatory CD56 + CD3 − cells to suppress autologous TILs suggests that patients with these cells might have reduced immune surveillance. To examine this possibility, we evaluated whether the presence of regulatory CD56 + CD3 − cells in TIL cultures corresponded to a difference in clinical outcomes for patients with HGSC in comparison to patients with fast TIL expansion who did not have a population of regulatory CD56 + CD3 − cells. When recurrence-free survival (RFS) was examined, the average time to recurrence was 12.6 months for patients with regulatory CD56 + CD3 − cells in their TIL cultures versus 24 months for patients who did not have regulatory CD56 + CD3 − cells in their TIL cultures (Fig. 4j) . The presence of regulatory ILCs in TIL cultures therefore corresponded to a shorter time to relapse. While we did not repeat these studies in an independent cohort, high CD56 expression in the annotated microarray data set published by Tothill et al. 34 was associated with a significant reduction in RFS time (Supplementary Fig. 10 ), supporting the interpretation that CD56 + CD3 − cells may be a negative prognostic biomarker for HGSC.
Our findings that some patients with HGSC have TIL cultures containing regulatory CD56 + CD3 − cells while other patients do not suggest that tumor microenvironment may play a role in recruiting and/or promoting the differentiation of immunosuppressive CD56 + CD3 − cells. It is important to note that the association between the presence of CD56 + CD3 − cells and poor TIL expansion is not restricted to HGSC, as we have observed a high proportion of CD56 + CD3 − cells in melanoma and breast cancer TIL cultures that did not expand well (data not shown). In the context of TIL-based adoptive cell therapy, depletion of CD56 + CD3 − cells in expansion protocols may represent a novel method to improve this immunotherapy.
The regulatory CD56 + CD3 − cells that we describe are CD56 hi CD16 − CD94 + NKG2D + KIR + NKp30 + NKp46 + lymphocytes that can produce IL-22 yet are NKp44 − ex vivo and that limit T cell cytokine production and expansion. While capable of making IFN-γ and TNF-α, regulatory CD56 + CD3 − cells do not actively secrete these cytokines in TIL cultures expanded in the presence of IL-2. The majority of cultures contained a high proportion of CD94 + cells and expressed various KIRs, which would point to these cells being of NK cell origin. However, other cultures displayed differences in the expression of NK cell-associated molecules, leaving the possibility of a heterogeneous CD56 + CD3 − ILC population in these individuals. However, our study clearly demonstrates that the ability of regulatory CD56 + CD3 − cells to suppress TILs involves NKp46, supporting a role for this NCR in regulating interactions with T cells.
Notably, ILCs and NK cells with immunosuppressive capacity in our study and others have been found to have many of the same characteristics as T reg cells. In addition to suppressing T cell expansion and cytokine production, some models have shown that suppressive NK cells/ILCs produce IL-10 (refs. 35, 36) , inhibit B cell function and memory 37, 38 , and dampen immune responses by modulating DC function [39] [40] [41] , as well as limiting immunity by killing CD8 + T cells 19, 20 . While the majority of studies have described immunosuppressive ILCs as NK cells, the various shared and distinct properties of suppressive ILCs when compared to conventional NK cells and other ILC subsets are not well defined. From this perspective, the origin and differentiation of regulatory ILCs must be better understood. The extent to which ILCs regulate immune responses in a multitude of contexts should be evaluated, as this is important for understanding human disease.
MeThoDs
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
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oNLINe MeThoDs
Tissue and blood specimens. This study was conducted according to the principles expressed in the Declaration of Helsinki. The Research Ethics Board (REB) of the University Health Network (UHN) approved the study. All patients provided written informed consent for the collection of samples. Fresh tissues were obtained from patients with ovarian cancer undergoing standardof-care surgical procedures (UHN REB 10-0335). Tissues were obtained from the UHN Biospecimen Sciences Program. Blood products for TIL growth and assays were obtained from donors with hemochromatosis who were undergoing therapeutic phlebotomy (UHN REB 06-0129).
Phenotypic and functional study restrictions. Functional and phenotypic experiments were performed using tissue from patients with confirmed HGSC and were chemotherapy naive at the time of surgery. Tissues were obtained from initial debulking surgeries. Clinicians providing patient outcome data, diagnosis, and analysis of IHC sections were blinded to TIL expansion rates and the outcomes of functional/phenotypic studies.
Media. The complete medium (CM) for initial TIL expansion was comprised of Iscove's modified Dulbecco's medium (IMDM) (Lonza) with 10% human plasma, 25 mM HEPES (Lonza), 100 U/ml penicillin, 100 µg/ml streptomycin (Lonza), 10 µg/ml gentamicin sulfate (Lonza), 2 mM l-glutamine (Lonza), 5.5 × 10 −5 M 2-mercaptoethanol (Invitrogen), and 6,000 IU/ml recombinant human IL-2 (Novartis). For enzyme dissociation medium, the following were added to IMDM: 1 mg/ml collagenase (Sigma), 100 µg/ml DNase I (pulmozyme, Roche), 10 µg/ml gentamicin sulfate, 2 mM l-glutamine, 1.25 µg/ml amphotericin B, 100 U/ml penicillin, and 100 µg/ml streptomycin. XH Media used for suppression assays consisted of X-Vivo 15 (Lonza) plus 5% human plasma, 100 U/ml penicillin, 100 µg/ml streptomycin (Lonza), and 2 mM l-glutamine (Lonza).
Tumor-infiltrating lymphocyte cultures. Methods for the initial TIL expansion are described in Nguyen et al. 26 . In brief, tissues were processed by mincing into ~1 mm 3 pieces and plated in 24-well tissue culture plates, or by enzymatic dissociation before plating at 1 × 10 6 cells per well. Cells were cultured in 2 ml of CM (containing 6,000 IU/ml recombinant human IL-2) per well in a humidified incubator with 5% CO 2 at 37 °C. During culture, half of the medium from each well was replaced with fresh CM three times a week, and wells were maintained at a cell concentration of 0.5-2 × 10 6 cells/ml. Each independent TIL culture was generally derived from one parental well; during subsequent expansion, all daughter wells derived from the same parental well were combined, mixed, and replated. "Fast" expansion rates refers to TIL cultures that yielded >30 × 10 6 cells on or before 4 weeks, "slow" refers to TIL cultures that achieved 2-29 × 10 6 cells by 4 weeks, and "no" refers to cultures that had cell yields below 2 × 10 6 cells at 4 weeks. TIL culturing was initially performed to assess whether enough cells could be expanded for adoptive T cell therapy clinical trials. Therefore, these criteria are based on the cell numbers needed within a short (maximum of 4 weeks) timeframe to seed rapid expansion protocols (REPs) in order to generate enough cells for infusion under clinical protocols. For cultures that were harvested before or after 4 weeks, the counts at the time of harvest were used to estimate whether the culture would have been categorized as "fast," "slow," or "no" at the 4-week mark. Therefore, some of the cultures in the "slow" category had >30 × 10 6 cells at the time of harvest (>4 weeks in culture).
Further expansion of TILS after depletion of regulatory ILCs. For all expansion and functional studies, CD56 + CD3 − cells were also CD14 − and CD19 − . TIL cultures with a high proportion of CD56 + CD3 − cells and a low expansion rate were thawed, replated at 5 × 10 6 cells/well, and rested in CM (containing 6,000 IU/ml IL-2) for 7 d. On day 7, TILs were depleted of CD56 + CD3 − cells by flow cytometry-based sorting. Cultures were then subjected to further expansion in CM in 24-well plates as follows: 1 × 10 4 TILs depleted of CD56 + CD3 − cells or non-sorted TILs, 1 × 10 6 TM-LCL Epstein-Barr virus (EBV)-transformed B-lymphoblastoid line (LCL) (kind gift from C. Yee (MD Anderson)) irradiated with 7,500 Gy, 5 × 10 6 allogeneic peripheral blood mononuclear cells (PBMCs) irradiated with 45 Gy, 30 ng/ml anti-CD3 antibody (OKT3, Miltenyi Biotec) and 600 IU/ml IL-2. Fresh CM containing IL-2 was added every 2-3 d. Cell counts were performed every 2-3 d in parallel with flow cytometric analysis of CD3, CD4, CD8, and CD56 expression. Cell counts were multiplied by the percentage of cells that were CD56 + CD3 − , CD4 + T cells (CD3 + CD4 + CD8 − ) or CD8 + T cells (CD3 + CD4 − CD8 + ) to calculate expansion yields. Suppression assays. CD56 + CD3 − cells and CD4 + and CD8 + T cells were purified by flow cytometry-based sorting (BD Aria). For all suppression assays, CD56 + CD3 − cells were also CD14 − and CD19 − . T cells were labeled with Cell Proliferation Dye (eBioscience) and then stimulated at 1 × 10 5 cells/well with anti-CD3-and anti-CD28-coated beads (Invitrogen) in the presence or absence of sorted autologous CD56 + CD3 − cells from the slowly expanding TIL cultures (regulatory CD56 + CD3 − cells) at a 1:4 ratio of CD56 + CD3 − cells to T cells. After 72 h, the number of cells present was determined, as was the proportions of cells expressing CD3, CD4, CD8, and CD56. Percentage suppression was calculated using the following formula commonly used to calculate suppression by T reg cells: suppression (%) = (1 -(TILs + CD56 + CD3 − cells/TILs)) × 100%. Cytokine suppression was determined by analysis of intracellular cytokine staining of sorted CD4 + and CD8 + T cells (1 × 10 5 cells/well) that had been stimulated for 72 h with anti-CD3-and anti-CD28-coated beads (Invitrogen) in the presence or absence of autologous purified regulatory CD56 + CD3 − cells. Cell Stimulation Cocktail (eBioscience) was used to restimulate T cells for 5-6 h, with brefeldin A (eBioscience) added halfway through the restimulation. Following surface staining, cells were fixed using Cytofix/Cytoperm buffer (BD). Intracellular cytokine staining was performed in Cytoperm buffer (BD) with monoclonal antibodies against TNF-α (BD, Mab11, 1:100) and IFN-γ (BD, B27, 1:100). Samples were acquired on a FACSCanto II (BD), and data were analyzed with FlowJo software.
For suppression assays involving supernatants from regulatory CD56 + CD3 − cells, supernatants from sorted CD56 + CD3 − cells were added every day for the duration of the assay and suppression was measured as above.
RNA preparation and RNA sequencing. CD56 + CD3 − CD19 − CD14 − cells from slowly growing TIL cultures that were confirmed to suppress TILs in functional assays (regulatory CD56 + CD3 − cells) and CD56 + CD3 − CD19 − CD14 − cells from rapidly expanding TIL cultures that did not suppress TILs in functional assays (CD56 + CD3 − cells) were sorted by flow cytometry. RNA was isolated using RNeasy Plus Mini kits (Qiagen). RNA preparations were quantified by High-Sensitivity RNA Qubit assay (Life Technologies/Thermo Fisher) and quality by Agilent Bioananlyzer. All samples in this study showed high RNA quality, having RINs between 8.1 and 9.8. 1.5 ng of total RNA per sample was used for library preparation using SMARTer Stranded Total RNA-seq Kit-Pico Input Mammalian (Clontech Laboratories). The paired-end libraries were sequenced on NextSeq 500 (Illumina) for 75 cycles. RNA-seq was performed by the Princess Margaret Genomics Centre (Toronto, Canada) RNA sequencing data analysis. For each sample, raw sequence files in FASTQ format containing an average of 150 million reads were aligned to the GRCh37 human reference genome using STAR v.2.4.2a assisted by the GENCODE v19 transcriptome model annotations 42 . Data alignment quality control measures were collected and verified using RNA-SeQC v1. 1.8 (ref. 43 ). Because of the limited DNA input used for sequencing, only highly expressed transcripts could be detected with sufficient sequencing read coverage ( Supplementary  Fig. 4) . Gene-level transcript abundances were quantified using RSEM v1.2.29 and is reported in units of transcripts per million (TPM) 44 . Gene expression heat maps were created by log 2 -transformed, upper-quartile-normalized TPM values using custom scripts in the R statistical environment. The DESeq2 R package was used to perform principal-component analysis and identify differentially expressed genes by using expected read counts generated by RSEM 45 . Differentially expressed genes with P values adjusted for multiple testing by FDR less than 0.05 and log 2 fold change greater than 1 are reported as statistically significant.
Flow cytometric analyses.
Surface marker staining for the following markers was performed in PBS at 4 °C for 30 min following Fc block:
